Key Takeaway: Skye Bioscience, a clinical-stage biotechnology company, will announce its 2025 financial results and business update on March 10, 2026. The announcement will be followed by a conference call to discuss the results. Skye is actively developing therapeutics for obesity, including a Phase 2a trial for nimacimab, a novel antibody.
Price reaction · baseline $0.7406 (2026-03-04 close) · hit pre-market · 2 other SKYE headline(s) in the window, move may be shared
day 0 close · peak
-0.4%
Market Sentiment Analysis
POSITIVE FACTORS
Skye Bioscience is focused on innovative therapeutic pathways.
The company is preparing to announce financial results, indicating transparency.
Conducting a Phase 2a clinical trial shows active development in obesity treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity
Full Press Release Details
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Tuesday, March 10th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 fourth quarter and full-year financial results and business update. An earnings press release will be issued after the market closes on March 10th.
The live webcast of the call can be accessed at the SkyeInvestor Relationswebsite, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay and transcript will be available at the same website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit:www.skyebioscience.com. Connect with us onXandLinkedIn.
Media Inquiries
Frequently Asked Questions
When will Skye Bioscience announce its financial results?
Skye Bioscience will announce its financial results on March 10, 2026.
What is the focus of Skye Bioscience?
Skye Bioscience focuses on developing therapeutics for obesity and metabolic health.
What is nimacimab?
Nimacimab is a negative allosteric modulating antibody being tested for obesity.
How can I access the conference call?
The conference call can be accessed via the Skye Investor Relations website.